Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic HPV-specific CD4+ T Cells in Advanced HPV16-associated Malignancies
NCT04713046Phase 2Active, not recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Oct 2023
- Primary completion
- Dec 2026
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Allogeneic HPV-specific CD4+ T cells in head and neck squamous cell carcinoma (HNSCC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Oct 2023; status: active, not recruiting.
02
Drugs
Allogeneic HPV-specific CD4+ T cells
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04713046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04713046.